Your browser doesn't support javascript.
loading
Parenchymal obliteration by renal masses: Functional and oncologic implications.
Kazama, Akira; Munoz-Lopez, Carlos; Attawettayanon, Worapat; Boumitri, Melissa; Maina, Eran; Lone, Zaeem; Rathi, Nityam; Lewis, Kieran; Campbell, Rebecca A; Palacios, Diego Aguilar; Kaouk, Jihad; Haber, Georges-Pascal; Haywood, Samuel; Almassi, Nima; Weight, Christopher J; Remer, Erick M; Ward, Ryan; Nowacki, Amy S; Campbell, Steven C.
Affiliation
  • Kazama A; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH; Department of Urology, Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Munoz-Lopez C; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
  • Attawettayanon W; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH; Division of Urology, Department of Surgery, Faculty of Medicine, Songklanagarind Hospital, Prince of Songkla University, Songkhla, Thailand.
  • Boumitri M; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
  • Maina E; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
  • Lone Z; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
  • Rathi N; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
  • Lewis K; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
  • Campbell RA; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
  • Palacios DA; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
  • Kaouk J; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
  • Haber GP; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
  • Haywood S; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
  • Almassi N; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
  • Weight CJ; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.
  • Remer EM; Imaging Institute, Cleveland Clinic, Cleveland OH.
  • Ward R; Imaging Institute, Cleveland Clinic, Cleveland OH.
  • Nowacki AS; Department of Quantitative Sciences, Cleveland Clinic, Cleveland, OH.
  • Campbell SC; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. Electronic address: campbes3@ccf.org.
Urol Oncol ; 42(8): 247.e11-247.e19, 2024 Aug.
Article in En | MEDLINE | ID: mdl-38729867
ABSTRACT

OBJECTIVES:

Most renal tumors merely displace nephrons while others can obliterate parenchyma in an invasive manner. Substantial parenchymal volume replacement (PVR) by renal cell carcinoma (RCC) may have oncologic implications; however, studies regarding PVR remain limited. Our objective was to evaluate the oncologic implications associated with PVR using improved methodology including more accurate and objective tools. PATIENTS/

METHODS:

A total of 1,222 patients with non-metastatic renal tumors managed with partial nephrectomy (PN) or radical nephrectomy (RN) at Cleveland Clinic (2011-2014) with necessary studies were retrospectively evaluated. Parenchymal volume analysis via semiautomated software was used to estimate split renal function and preoperative parenchymal volumes. Using the contralateral kidney as a control, %PVR was defined (parenchymal volumecontralateral-parenchymal volumeipsilateral) normalized by parenchymal volumecontralateral x100%. PVR was determined preoperatively and not altered by management. Patients were grouped by degree of PVR minimal (<5%, N = 566), modest (5%-25%, N = 414), and prominent (≥25%, N = 142). Kaplan-Meier was used to evaluate survival outcomes relative to degree of PVR. Multivariable Cox-regression models evaluated predictors of recurrence-free survival (RFS).

RESULTS:

Of 1,122 patients, 801 (71%) were selected for PN and 321 (29%) for RN. Overall, median tumor size was 3.1 cm and 6.8 cm for PN and RN, respectively, and median follow-up was 8.6 years. Median %PVR was 15% (IQR = 6%-29%) for patients selected for RN and negligible for those selected for PN. %PVR correlated inversely with preoperative ipsilateral GFR (r = -0.49, P < 0.01) and directly with advanced pathologic stage, high tumor grade, clear cell histology, and sarcomatoid features (all P < 0.01). PVR≥25% associated with shortened recurrence-free, cancer-specific, and overall survival (all P < 0.01). Male sex, ≥pT3a, tumor grade 4, positive surgical margins, and PVR≥25% independently associated with reduced RFS (all P < 0.02).

CONCLUSIONS:

Obliteration of normal parenchyma by RCC substantially impacts preoperative renal function and patient selection. Our data suggests that increased PVR is primarily driven by aggressive tumor characteristics and independently associates with reduced RFS, although further studies will be needed to substantiate our findings.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Kidney Neoplasms / Nephrectomy Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Urol Oncol Journal subject: NEOPLASIAS / UROLOGIA Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Kidney Neoplasms / Nephrectomy Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Urol Oncol Journal subject: NEOPLASIAS / UROLOGIA Year: 2024 Document type: Article Affiliation country: